RecruitingNot Applicable

Predictive Effect of TGF-β and INS-PI3K-AKT Related Proteins for POD in Diabetes Patients

China180 participantsStarted 2024-05-20

Plain-language summary

To investigate the relationship between POD, TGF-β and INS-PI3K-AKT signaling pathway related proteins (ADNP, MAP6, PGC-1α) in diabetic patients

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥65 years
✓. History of diabetes ≥2 years and Glycated hemoglobin ≥6.5% or no history of diabetes and normal blood glucose
✓. The ASA rating is Class I to III
✓. The elderly patients of limited thoracic and abdominal tumor surgery

Exclusion criteria

✕. Refused to participate
✕. Previous history of schizophrenia, epilepsy, Parkinson's disease
✕. History of alcohol abuse or drug dependence
✕. Patients with ASA grade IV and above
✕. Severe visual or hearing impairment, can not cooperate with the completion of cognitive function tests
✕. Participants in other clinical trials within the last two months
✕. Patients with severe arrhythmia or cardiac dysfunction(EF\<40%)
✕. There was a clear history of neurological and psychiatric problems or long-term use of sedatives or antidepressants

What they're measuring

The correlation between preoperative plasma levels of TGF-β, ADNP, MAP6, PGC-1α and the incidence of delirium within 3 days after operation was analyzed.

Timeframe: 2024-05 to 2026-06

Trial details

NCT IDNCT06426953

SponsorXie Kangjie

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-30

Contact for this trial

Kangjie Xie, MD

8613516721870 xiekj@zjcc.org.cn

View on ClinicalTrials.gov More Diabetes trials